Preclinical data consistently indicate that inhibition of the RAS-RAF-MEK-ERK pathway results in an increased autophagy dependence in cancers driven by KRAS or BRAF mutations (90% of pancreatic cancer) [49,141]. This evidence concerns the gene KRAS and pancreatic neoplasm.